{"id":"NCT03150875","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","briefTitle":"A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC","officialTitle":"Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase 3 Study (ORIENT-3)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-01","primaryCompletion":"2023-02-22","completion":"2023-02-22","firstPosted":"2017-05-12","resultsPosted":"2021-06-23","lastUpdate":"2023-02-28"},"enrollment":290,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"IBI308","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":[]}],"arms":[{"label":"IBI308","type":"EXPERIMENTAL"},{"label":"docetaxel","type":"ACTIVE_COMPARATOR"}],"summary":"Clinical trial results demonstrate that anti-PD-1 antibodies prolonged OS to approximately 9 months compared with 6 months in docetaxel group. Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.\n\nAdditionally, the correlation between PD-L1 expression and the response to IBI308 treatment in Chinese squamous cell NSCLC patients as well as the role of irRECIST in immune checkpoint inhibitor treatment evaluation will also be assessed","primaryOutcome":{"measure":"Overall Survival","timeFrame":"Through database cutoff date of 31-July-2020 (up to approximately 35 months)","effectByArm":[{"arm":"Sintilimab","deltaMin":11.79,"sd":null},{"arm":"Docetaxel","deltaMin":8.25,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":2,"countries":["China"]},"refs":{"pmids":["36336841"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":56,"n":144},"commonTop":["Anaemia","Asthenia","Decreased appetite","Pyrexia","Cough"]}}